[go: up one dir, main page]

WO2005026737A3 - Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a4 (slc22a4) - Google Patents

Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a4 (slc22a4) Download PDF

Info

Publication number
WO2005026737A3
WO2005026737A3 PCT/EP2004/009929 EP2004009929W WO2005026737A3 WO 2005026737 A3 WO2005026737 A3 WO 2005026737A3 EP 2004009929 W EP2004009929 W EP 2004009929W WO 2005026737 A3 WO2005026737 A3 WO 2005026737A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
slc22a4
therapeutics
diagnostics
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/009929
Other languages
French (fr)
Other versions
WO2005026737A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2005026737A2 publication Critical patent/WO2005026737A2/en
Publication of WO2005026737A3 publication Critical patent/WO2005026737A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a human SLC22A4 which is associated with the cardiovascular diseases, cancer, gastroenterological diseases, inflammation, respiratory diseases, hematological diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, gastroenterological diseases, inflammation, respiratory diseases, hematological diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of SLC22A4 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/009929 2003-09-18 2004-09-07 Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a4 (slc22a4) Ceased WO2005026737A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03020577 2003-09-18
EP03020577.7 2003-09-18

Publications (2)

Publication Number Publication Date
WO2005026737A2 WO2005026737A2 (en) 2005-03-24
WO2005026737A3 true WO2005026737A3 (en) 2005-06-23

Family

ID=34306756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/009929 Ceased WO2005026737A2 (en) 2003-09-18 2004-09-07 Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a4 (slc22a4)

Country Status (1)

Country Link
WO (1) WO2005026737A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761784B1 (en) * 2004-05-24 2016-10-26 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002099053A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Slc22as as modifiers of the p53 pathway and methods of use
WO2003054011A2 (en) * 2001-12-21 2003-07-03 Ellipsis Biotherapeutics Corporation Polymorphisms of the octn1 and octn2 cation transporters associated with inflammatory bowel disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002099053A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Slc22as as modifiers of the p53 pathway and methods of use
WO2003054011A2 (en) * 2001-12-21 2003-07-03 Ellipsis Biotherapeutics Corporation Polymorphisms of the octn1 and octn2 cation transporters associated with inflammatory bowel disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENISON STACY R ET AL: "Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer.", GENES CHROMOSOMES AND CANCER, vol. 38, no. 1, September 2003 (2003-09-01), pages 40 - 52, XP008040698, ISSN: 1045-2257 *
KOEPSELL HERMANN ET AL: "The SLC22 drug transporter family.", PFLUEGERS ARCHIV EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 447, no. 5, February 2004 (2004-02-01), pages 666 - 676, XP002311398, ISSN: 0031-6768 *
TAMAI I ET AL: "Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1.", FEBS LETTERS. 8 DEC 1997, vol. 419, no. 1, 8 December 1997 (1997-12-08), pages 107 - 111, XP002311397, ISSN: 0014-5793 *
WU^A X ET AL: "Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1466, no. 1-2, 1 June 2000 (2000-06-01), pages 315 - 327, XP004273247, ISSN: 0005-2736 *

Also Published As

Publication number Publication date
WO2005026737A2 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
ATE471520T1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH THE G-PROTEIN-COUPLED RECEPTOR ADIPOR1 (ADIPOR1).
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005026737A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a4 (slc22a4)
WO2005026724A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a5 (slc22a5)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005040818A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter flipt1 (flipt1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2005029085A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a11 (slc22a11)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005040791A3 (en) Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr)
WO2005026736A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a2 (slc22a2)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2005093423A3 (en) Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2005026738A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a9 (slc22a9)
WO2004071377A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase